Journal of Clinical Oncology, Vol 11, 850-856, Copyright © 1993 by American Society of Clinical Oncology

ARTICLES

Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood

RJ Packer, B Lange, J Ater, HS Nicholson, J Allen, R Walker, M Prados, R Jakacki, G Reaman and MN Needles
Department of Neurology, Children's National Medical Center, Washington, DC 20010.

PURPOSE: This study investigates the response rate to and toxicity of carboplatin and vincristine in children with recurrent low-grade gliomas (LGGs) or patients younger than 60 months with newly diagnosed LGGs. PATIENTS AND METHODS: Twenty-three children with recurrent and 37 children with newly diagnosed LGGs were treated with a 10-week induction cycle of carboplatin and vincristine, followed by maintenance treatment with the same drugs. Patients were evaluated for response to treatment and toxicity. RESULTS: Twelve of 23 (52% +/- 10%; 95% confidence interval [CI], 0.32 to 0.72) assessable children with recurrent disease had an objective response to treatment, which included a greater than 50% reduction in tumor size in seven of 23 (30% +/- 10%; 95% CI, 0.10 to 0.50). Twenty-three of 37 (62% +/- .08; 95% CI, 0.46 to 0.78) of newly diagnosed patients had an objective response, 16 of 37 (43% +/- 0.08%; 95% CI, 0.27 to 0.59) with greater than 50% reduction in tumor size. The majority of those with an objective response had diencephalic tumors (n = 29), but children with thalamic (n = 2), cortical (n = 1), and brain stem (n = 2) LGGs also responded to treatment. Of the 35 patients with objective response to treatment, the maximum response was seen in 25 after completion of induction and in the remaining 10 after two to six cycles of maintenance treatment. Forty-nine of 53 (92% +/- .04%) patients who were stable or improved after induction remain without progressive disease (PD). Hematologic toxicity was common, but resulted in cessation of therapy in only one patient. Six children have been removed from the study because of allergic reactions, which were considered to be carboplatin-associated. CONCLUSION: Carboplatin and vincristine have activity in children with recurrent and newly diagnosed progressive LGGs. Objective responses to treatment after chemotherapy can be seen. This drug regimen is relatively well tolerated, and further studies are indicated to define the role of this combination of drugs in children with newly diagnosed LGGs.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. Sawamura, Y. Kamoshima, T. Kato, T. Tajima, and J. Tsubaki Chemotherapy with Cisplatin and Vincristine for Optic Pathway/Hypothalamic Astrocytoma in Young Children Jpn. J. Clin. Oncol., May 1, 2009; 39(5): 277 - 283. [Abstract] [Full Text] [PDF]

				C F Parsa and S Givrad Pilocytic astrocytomas as hamartomas: implications for treatment Br. J. Ophthalmol., January 1, 2008; 92(1): 3 - 6. [Full Text] [PDF]

				S. S. Donaldson, F. Laningham, and P. G. Fisher Advances Toward an Understanding of Brainstem Gliomas J. Clin. Oncol., March 10, 2006; 24(8): 1266 - 1272. [Abstract] [Full Text] [PDF]

				V. Laithier, J. Grill, M.-C. Le Deley, M.-M. Ruchoux, D. Couanet, F. Doz, F. Pichon, H. Rubie, D. Frappaz, J.-P. Vannier, et al. Progression-Free Survival in Children With Optic Pathway Tumors: Dependence on Age and the Quality of the Response to Chemotherapy--Results of the First French Prospective Study for the French Society of Pediatric Oncology J. Clin. Oncol., December 15, 2003; 21(24): 4572 - 4578. [Abstract] [Full Text] [PDF]

				J. A. Quinn, D. A. Reardon, A. H. Friedman, J. N. Rich, J. H. Sampson, J. M. Provenzale, R. E. McLendon, S. Gururangan, D. D. Bigner, J. E. Herndon II, et al. Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma J. Clin. Oncol., February 15, 2003; 21(4): 646 - 651. [Abstract] [Full Text] [PDF]

				M. Massimino, F. Spreafico, G. Cefalo, R. Riccardi, J. D. Tesoro-Tess, L. Gandola, D. Riva, A. Ruggiero, L. Valentini, E. Mazza, et al. High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma J. Clin. Oncol., October 15, 2002; 20(20): 4209 - 4216. [Abstract] [Full Text] [PDF]

				S. K. Ogle, M. M. Rose, and C. T. Wildes Development and Implementation of a Carboplatin Desensitization Protocol for Children with Neurofibromatosis, Type 1 and Hypersensitivity Reactions in an Outpatient Oncology Clinic Journal of Pediatric Oncology Nursing, July 1, 2002; 19(4): 122 - 126. [Abstract] [PDF]

				S. Gururangan, C. M. Cavazos, D. Ashley, J. E. Herndon II, C. S. Bruggers, A. Moghrabi, D. L. Scarcella, M. Watral, S. Tourt-Uhlig, D. Reardon, et al. Phase II Study of Carboplatin in Children With Progressive Low-Grade Gliomas J. Clin. Oncol., July 1, 2002; 20(13): 2951 - 2958. [Abstract] [Full Text] [PDF]

				T. E.G. Hassall, A. E. Mitchell, and D. M. Ashley Carboplatin chemotherapy for progressive intramedullary spinal cord low-grade gliomas in children: Three case studies and a review of the literature Neuro-oncol, October 1, 2001; 3(4): 251 - 257. [PDF]

				E. Osztie, P. Várallyay, N. D. Doolittle, C. Lacy, G. Jones, H. S. Nickolson, and E. A. Neuwelt Combined Intraarterial Carboplatin, Intraarterial Etoposide Phosphate, and IV Cytoxan Chemotherapy for Progressive Optic-Hypothalamic Gliomas in Young Children AJNR Am. J. Neuroradiol., May 1, 2001; 22(5): 818 - 823. [Abstract] [Full Text]

				D. H. Mahoney Jr., M. E. Cohen, H. S. Friedman, J. L. Kepner, L. Gemer, J. W. Langston, H. E. James, P. K. Duffner, and L. E. Kun Carboplatin is effective therapy for young children with progressive optic pathway tumors: A Pediatric Oncology Group phase II study Neuro-oncol, October 1, 2000; 2(4): 213 - 220. [Abstract] [PDF]

				D. H. Gutmann, A. Aylsworth, J. C. Carey, B. Korf, J. Marks, R. E. Pyeritz, A. Rubenstein, and D. Viskochil The Diagnostic Evaluation and Multidisciplinary Management of Neurofibromatosis 1 and Neurofibromatosis 2 JAMA, July 2, 1997; 278(1): 51 - 57. [Abstract] [PDF]

				A Shuper, G Horev, L Kornreich, S Michowiz, R Weitz, R Zaizov, and I J Cohen Visual pathway glioma: an erratic tumour with therapeutic dilemmas Arch. Dis. Child., March 1, 1997; 76(3): 259 - 263. [Abstract] [Full Text]

				I. F. Pollack Brain Tumors in Children N. Engl. J. Med., December 1, 1994; 331(22): 1500 - 1507. [Full Text]

				Media Review: Videotapes Journal of Pediatric Oncology Nursing, January 1, 1993; 10(4): 161 - 165. [PDF]